GUIDELINES
EHRA Position paper

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?

Nikolaos Dagres EHRA Chair1 | Tze-Fan Chao APHRS Co-Chair2 |
Guilherme Fenelon LAHRS Co-Chair3 | Luis Aguinaga4 | Daniel Benhayon5 |
Emelia J. Benjamin6 | T. Jared Bunch7 | Lin Yee Chen8 | Shih-Ann Chen2 |
Francisco Darrieux9 | Angelo de Paola10 | Laurent Fauchier11 | Andreas Goette12 |
Jonathan Kalman13 | Lalit Kalra14 | Young-Hoon Kim15 | Deirdre A. Lane16,17 |
Gregory Y.H. Lip16,17 | Steven A. Lubitz18 | Manlio F. Márquez19 |
Tatjana Potpara20,21 | Domingo Luis Pozzer22 | Jeremy N. Ruskin18 | Irina Savelieva23 |
Wee Siong Teo24 | Hung-Fat Tse25 | Atul Verma26 | Shu Zhang27 | Mina K. Chung HRS Co-Chair28

Reviewers: William-Fernando Bautista-Vargas (Colombia), Chern-En Chiang (Taiwan), Alejandro Cuesta (Uruguay), Gheorghe-Andrei Dan (Romania), David S. Frankel (USA), Yutao Guo (People's Republic of China), Robert Hatala (Slovakia), Young Soo Lee (Republic of Korea), Yuji Murakawa (Japan), Cara N. Pellegrini (USA), Claudio Pinho (Brazil), David J. Milan (USA), Daniel P. Morin (USA), Elenir Nadalin (Brazil), George Ntaios (Greece), Mukund A. Prabhu (India, Australia), Marco Proietti (UK, Italy), Lena Rivard (Canada), Mariana Valentino (Argentina), and Alena Shantsila (Reviewer Coordinator) (UK)

1Department of Electrophysiology, Heart Center Leipzig, Leipzig, Germany
2Taipei Veterans General Hospital, Taipei, Taiwan
3Hospital Israelita Albert Einstein, São Paulo, Brazil
4Centro Privado de Cardiología, Tucumán, Argentina
5Cardiac and Vascular Institute, Memorial Health, Hollywood, FL, USA
6Boston University Schools of Medicine and Public Health, Framingham Heart Study, Boston, MA, USA

This article has been co-published with permission in EP Europace, HeartRhythm and Journal of Arrhythmia. All rights reserved. © 2018 the European Heart Rhythm Association, a registered branch of the European Society of Cardiology, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society and the Latin American Heart Rhythm Society (formerly Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiología). The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2018 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.
Correspondence
Nikolaos Dagres,
Department of Electrophysiology,
Heart Center Leipzig, Leipzig, Germany.
Email: dagresnila@gmail.com

KEYWORDS
arrhythmias, Asia Pacific Heart Rhythm Society, cognitive, dementia, European Heart Rhythm Association, Heart Rhythm Society, Latin American Heart Rhythm Society

Table of Contents
1 Introduction 3
1.1 Evidence review 3
1.2 Relationships with industry and other conflicts 4
2 Decline of cognitive function: terminology and epidemiology 4
2.1 Terminology: cognitive decline, mild cognitive impairment, and dementia 4
2.2 Epidemiology of dementia 4
3 Methods for assessment of cognitive function 4
4 Role of imaging 5
5 Atrial fibrillation and cognitive function 8
5.1 Atrial fibrillation, overt stroke, and cognitive function 8
5.2 Atrial fibrillation, silent stroke, and cognitive function 9
5.3 Atrial fibrillation and cognitive function in the absence of stroke 10
5.4 Assessment of cognitive function in atrial fibrillation patients in clinical practice 11
(Continues)

5.5 Prevention of cognitive dysfunction in atrial fibrillation patients 12
6 Other arrhythmias and cognitive dysfunction 13
6.1 Cognitive dysfunction in patients with regular supraventricular tachycardias 13
6.2 Cognitive impairment after cardiac arrest 13
6.2.1 Brain injury after non-fatal cardiac arrest 13
6.2.2 Memory impairment after cardiac arrest 14
6.2.3 Therapeutic hypothermia to prevent cognitive impairment after cardiac arrest 14
6.3 Cardiac implantable electronic devices and cognitive dysfunction 14
6.4 Catheter ablation 15
6.5 Implications for electrophysiological procedures and cognitive function 16
7 Current knowledge gaps, future directions, and areas for research 19
8 Recommendations 20
References 20
1 | INTRODUCTION

This expert consensus statement of the European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS) summarizes the consensus of the international writing group and is based on a thorough review of the medical literature regarding cognitive function in arrhythmias. The document is intended to describe the impact of different types of arrhythmias on cognitive function, to highlight possible risk markers for cognitive decline and to formulate implications for clinical practice regarding follow-up methods, prevention and treatment strategies. Our objective is to raise awareness of cognitive function among physicians treating patients with arrhythmias and to provide them with practical proposals that may lead to improvement of patient care in this regard.

This document reviews terminology and the epidemiology of cognitive dysfunction, methods for assessment of cognitive function and the role of imaging. Recent studies have suggested possible associations between cognitive decline and atrial fibrillation (AF). We review the reported literature on AF and cognitive function, including the scenarios of AF with overt stroke, silent stroke, or no stroke, and then make recommendations for assessment of cognitive function and prevention of cognitive decline in patients with AF in clinical practice. The document also reviews the association of other arrhythmias and cognitive dysfunction, including settings such as post-cardiac arrest, cardiac implantable devices, such as implantable cardioverter-defibrillators (ICDs) and pacemakers, or ablation procedures. Implications for electrophysiological procedures and cognitive function are discussed. Long QT syndrome and cognitive function is not addressed in the document. For quick reference, sub-chapters are followed by a short section on consensus recommendations. The document concludes with a summary of consensus statements, current knowledge gaps, and future directions of research.

1.1 | Evidence review

Members of the Task Force were asked to perform a detailed literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes for which data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered, as are frequency of follow-up and cost-effectiveness. In controversial areas, or with regard to issues without evidence other than usual clinical practice, a consensus was achieved by agreement of the expert panel after thorough deliberations. This document was prepared by the Task Force with representation from EHRA, HRS, APHRS, and LAHRS. The document was peer-reviewed by official external reviewers representing EHRA, HRS, APHRS, and LAHRS.

Consensus statements are evidence-based and derived primarily from published data or determined through consensus opinion if data are not available. Current systems of ranking level of evidence are becoming complicated in a way that their practical utility might be compromised. In contrast to guidelines, we opted for an easier and user-friendly system of ranking using “coloured hearts” that should allow physicians to easily assess the current status of the evidence and consequent guidance (Table 1). This EHRA grading of consensus statements does not have separate definitions of the level of evidence. This categorization, used for consensus statements, must not be considered as directly similar to that used for official society guideline recommendations, which apply a classification (Class I-III) and level of evidence (A, B, and C) to recommendations used in official guidelines.

Thus, a green heart indicates a "should do this" consensus statement or indicated treatment or procedure that is based on at least one randomized trial, or is supported by strong observational evidence that it is beneficial and effective. A yellow heart indicates general agreement and/or scientific evidence favouring a "may do this" statement or the usefulness/efficacy of a treatment or procedure. A "yellow heart" symbol may be supported by randomized trials based on a small number of patients or which is not widely applicable. Treatment strategies for which there is scientific evidence of potential harm and should not be used ("do not do this") are indicated by a red heart.

Finally, this is a consensus document that includes evidence and expert opinions from several countries. The pharmacological and

TABLE 1 Scientific rationale of recommendations

<table>
<thead>
<tr>
<th>Definitions related to a treatment or procedure</th>
<th>Consensus statement instruction</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific evidence that a treatment or procedure is beneficial and effective. Requires at least one randomized trial, or is supported by strong observational evidence and authors’ consensus (as indicated by an asterisk)</td>
<td>&quot;Should do this&quot;</td>
<td>♠️❤️</td>
</tr>
<tr>
<td>General agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or procedure. May be supported by randomized trials based on a small number of patients or which is not widely applicable</td>
<td>&quot;May do this&quot;</td>
<td>❤️</td>
</tr>
<tr>
<td>Scientific evidence or general agreement not to use or recommend a treatment or procedure</td>
<td>&quot;Do not do this&quot;</td>
<td>❤️❤️</td>
</tr>
</tbody>
</table>

*This categorization for our consensus document should not be considered as being directly similar to that used for official society guideline recommendations which apply a classification (I-III) and level of evidence (A, B, and C) to recommendations.
2.1 | Terminology: cognitive decline, mild cognitive impairment, and dementia

Cognitive decline that is greater than expected from normal aging can be ascertained from changes in standardized cognitive test scores over time. Examples of standardized cognitive tests that evaluate different cognitive domains include Delayed Word Recall test (short-term memory),

Digit Symbol Substitution test (executive function and processing speed),

and Word Fluency test (executive function and expressive language).

Mild cognitive impairment is an intermediate stage between the expected cognitive decline of normal aging and the more serious abnormality of dementia. Mild cognitive impairment is characterized by declines in cognitive function and objective long-term cognitive deficit that does not affect activities of daily living.

Dementia is defined as deficits in ≥2 cognitive domains that represent a decline from previous level of functioning and that are sufficiently severe to affect activities of daily living. Both mild cognitive impairment and dementia can be further classified into subtypes.

Mild cognitive impairment can be sub-typed into four groups (based on the scheme adopted by the National Institute on Aging Alzheimer’s Disease Centers Program for the Uniform Data Set) as amnestic or non-amnestic, single or multiple domain. Dementia can be classified into aetiologic diagnoses: Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal dementia, and other dementias.

2.2 | Epidemiology of dementia

A recent systematic review provided some insights into the contemporary (1980-2009) prevalence of dementia in individuals aged ≥60 years in 21 Global Burden of Disease regions: age-standardized prevalence for those aged ≥60 years varied in a narrow band (5-7% in most world regions), with a higher prevalence in Latin America (8.5%), and a lower prevalence in the four sub-Saharan African regions (2-4%). Approximately 35.6 million people lived with dementia worldwide in 2010, with numbers expected to almost double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58% of all people with dementia lived in countries with low or middle incomes, with this proportion anticipated to rise to 63% in 2030 and 71% in 2050. Thus, dementia is a burgeoning global public health problem that prompts an urgent and more comprehensive understanding of its risk factors with the aim to discover novel prevention strategies.

The burden of dementia is rapidly increasing owing to the aging of the population. Other than advancing age, risk factors for dementia, particularly vascular dementia, have been extensively studied from an epidemiological perspective. Broadly, they can be classified as dementia due to non-modifiable risk factors, lifestyle factors, physiological risk factors, or clinical cardiovascular or cerebrovascular disease. Selected risk factors are shown in Table 2 and include many of the risk factors included in stroke risk scores in AF.

3 | METHODS FOR ASSESSMENT OF COGNITIVE FUNCTION

Impairments of cognitive function often can be subtle and insidious, presenting as missed appointments, mislaying objects, or minor problems at work or home, which are often attributed to stress, age, or pressure of work. Any difference in appearance, behaviour or functioning reported by the patient or the family should alert the physician to the need for a formal assessment. The aim of this assessment is to examine higher cortical functions (attention, orientation, memory, language, praxis, and executive function) from patient narrative, collateral information from families, clinical examination, and standardized tests of cognitive function. For assessment of cognitive impairment, a combination of tools and methods are used (Table 3).

During the assessment, particular attention needs to be paid to aspects such as vagueness with dates and events, repetition, inappropriate, or fixed ideas. A collateral account from a caregiver can provide clarification of symptoms and their duration. Specific areas requiring attention include features of depression, neurological or psychiatric diseases, drug/medication use, uncorrected visual and hearing problems, infections, cardiac/respiratory/renal failure, or fast AF, all of which potentially affect cognitive function. Investigations include complete blood count, blood glucose, creatinine, electrolytes, calcium, liver and thyroid function tests, serum folate, and B12 levels. Syphilis serology should be checked in high-risk patients. Magnetic resonance imaging can be helpful to estimate cerebrovascular and degenerative disease load and exclude tumours or normal pressure hydrocephalus.

A list of cognitive assessment tools is provided in Table 4. Several tools are available for cognitive assessment, but there is no consensus on a preferred approach. The choice of tool should vary with the purpose of testing and other factors, such as availability,
familiarity, and feasibility. Common assessment tools are the two-step general practitioner assessment of cognition (GPCOG) and the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE), both of which have been validated in large populations. Standardized assessment tools are not diagnostic instruments and results need to be interpreted in the context of all available evidence.

4 | ROLE OF IMAGING

Brain imaging studies can identify vascular disease as a cause of dementia. In an autopsy study of patients with dementia, pathological diagnoses implicated vascular disease in about 25% of subjects, half of whom had pure vascular disease. The three main causes of vascular cognitive impairment are large vessel strokes, small vessel disease (SVD), and micro- haemorrhages. The preferred imaging modality, magnetic resonance imaging (MRI), has high specificity and sensitivity for detecting these changes and is an important adjunct to clinical and psychometric assessments.
TABLE 4  Comparison of commonly used brief cognitive assessment tools and a list of more complex cognitive assessments

<table>
<thead>
<tr>
<th>Cognitive assessment tool</th>
<th>Number of items</th>
<th>Average completion time in elderly (≥65 years) patients, minutes</th>
<th>Equipment required</th>
<th>Cognitive domains assessed</th>
<th>Equipment required</th>
<th>Informant component</th>
<th>Range of scoresa</th>
<th>Cut-off indicating cognitive impairmentb</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMT435</td>
<td>4</td>
<td>1</td>
<td>Verbal</td>
<td>Semantic, STM, Remote</td>
<td></td>
<td></td>
<td>0-4</td>
<td>0-4</td>
</tr>
<tr>
<td>CDT36</td>
<td>3</td>
<td>2</td>
<td>Pen and paper</td>
<td>+</td>
<td></td>
<td></td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td>SIS37</td>
<td>6</td>
<td>2</td>
<td>Verbal</td>
<td>+</td>
<td></td>
<td></td>
<td>≤37d ≤38</td>
<td>0-6</td>
</tr>
<tr>
<td>Mini-Cog39</td>
<td>6</td>
<td>3</td>
<td>Pen and paper</td>
<td>+</td>
<td></td>
<td></td>
<td>0-5</td>
<td>0-5</td>
</tr>
<tr>
<td>AMT35</td>
<td>10</td>
<td>3</td>
<td>Verbal</td>
<td>+</td>
<td></td>
<td></td>
<td>0-10</td>
<td>0-10</td>
</tr>
<tr>
<td>MIS40</td>
<td>4</td>
<td>4</td>
<td>Verbal</td>
<td>+</td>
<td></td>
<td></td>
<td>0-8</td>
<td>0-8</td>
</tr>
<tr>
<td>6CIT41</td>
<td>6</td>
<td>5</td>
<td>Verbal</td>
<td>+</td>
<td></td>
<td></td>
<td>0-28</td>
<td>0-28</td>
</tr>
<tr>
<td>GPCOG42</td>
<td>9</td>
<td>5-6</td>
<td>Pen and paper</td>
<td>+</td>
<td></td>
<td></td>
<td>0-4; 5-8 proceed with InQ</td>
<td>0-4</td>
</tr>
<tr>
<td>MMSE43,c</td>
<td>30</td>
<td>8</td>
<td>Pen, paper, and watch</td>
<td>+</td>
<td></td>
<td></td>
<td>0-30</td>
<td>0-30</td>
</tr>
<tr>
<td>MOCA44</td>
<td>30</td>
<td>10</td>
<td>Pen and paper</td>
<td>+</td>
<td></td>
<td></td>
<td>&lt;24 ≤23 if ≤12 years education; ≤25 if higher education</td>
<td>0-30</td>
</tr>
<tr>
<td>OCS45</td>
<td>10 tasks</td>
<td>15-20</td>
<td>Pen and paper</td>
<td>+</td>
<td></td>
<td></td>
<td>&lt;26 ≤2; add 1 point if ≤12 years education</td>
<td>-1 to 111</td>
</tr>
</tbody>
</table>

(Continues)
<table>
<thead>
<tr>
<th>Cognitive assessment tool</th>
<th>Number of items</th>
<th>Average completion time in elderly patients, minutes</th>
<th>Cognitive domains assessed</th>
<th>Equipment required</th>
<th>Semantic</th>
<th>STM</th>
<th>Remote</th>
<th>Visuospatial/ constructional praxis</th>
<th>Frontal/ executive</th>
<th>Orientation</th>
<th>Attention/ calculation</th>
<th>Language</th>
<th>Informant component</th>
<th>Cut-off indicating cognitive impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE&lt;sup&gt;46&lt;/sup&gt;</td>
<td>100</td>
<td>20</td>
<td></td>
<td>Pen, paper, watch and specific pictures</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>&lt;87&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>3MS&lt;sup&gt;47&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cutoff not specifically tested</td>
</tr>
<tr>
<td>CAMCOG&lt;sup&gt;48&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cutoff not specifically tested</td>
</tr>
<tr>
<td>CASI&lt;sup&gt;49&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cutoff not specifically tested</td>
</tr>
<tr>
<td>IQCODE&lt;sup&gt;50&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cutoff not specifically tested</td>
</tr>
</tbody>
</table>

More complex and extended cognitive examinations<sup>d</sup>

- 3MS<sup>47</sup>: extension of MMSE including verbal fluency and further memory testing; overall score 0-100; score <78 for those aged ≥65 years
- CAMCOG<sup>48</sup>: 80 minutes, structured history taking from patient and informant, structured examination and mental state assessment
- CASI<sup>49</sup>: questions form MMS and 3MS; scored 0-100 takes 15-20 minutes to complete
- IQCODE<sup>50</sup>: 16-item informant questionnaire comparing patient cognition now to 10-years ago; each rated on five-point Likert scale

<sup>a</sup>Range of scores.
<sup>b</sup>Cut-off indicating cognitive impairment.
<sup>c</sup>Standardized MMSE is also available.
<sup>d</sup>Not an exhaustive list.
However, imaging findings need to be interpreted in the clinical context because of uncertain correlation with symptoms or psychometric test performance.53

Structural imaging is undertaken using T1- and T2-weighted spin echo sequences to identify infarcts and macro-haemorrhages, T2*-weighted gradient echo sequences for micro-haemorrhages, fluid-attenuated inversion recovery imaging for incomplete infarcts and leukoaraiosis and diffusion-weighted imaging (DWI) for visualising the integrity of functional network fibre tracts not captured by other imaging techniques. Magnetic resonance imaging provides several markers of micro- and macrostructural organization that are sensitive to change, related to clinical endpoints and has the potential to predict cognitive trajectories in individual patients.53

Magnetic resonance imaging signs that predict potential cognitive impairments include (i) large or bilateral infarcts due to large vessel disease; (ii) strategic infarcts secondary to embolization in regions as hippocampus, dominant thalamus, medial temporal, and deep frontal; (iii) lacunes, white matter hyperintensities (leukoaraiosis) and haemorrhages associated with SVD; and (iv) lobar micro-haemorrhages representative of amyloid angiopathies. In addition, although global cerebral atrophy and/or medial-temporal lobe atrophy may suggest an element of Alzheimer’s disease (mixed cognitive impairment), subcortical infarcts, per se, may trigger progressive focal thinning and grey matter atrophy in connected temporal and frontal cortical areas.31

Imaging of cerebral blood flow using arterial spin labelling, metabolic imaging with proton magnetic resonance spectroscopy and dynamic contrast-enhanced MRI can help estimate the extent of injury, vessel permeability, and inflammation. Although these can differentiate between dementias and separate pathological changes from those due to aging, they remain research techniques with limited clinical application.

Positron emission tomography scans have also been used to assess brain metabolic function, inflammation, amyloid or tau protein, which may be helpful in differentiating some types of dementia.53

An overview of commonly used imaging modalities in cognitive impairment is provided in Table 5.

### TABLE 5 Commonly used brain imaging modalities in cognitive impairment

<table>
<thead>
<tr>
<th>Modality</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT</td>
<td>Large infarcts/haemorrhage, established small vessel disease, other pathologies, limited application</td>
</tr>
<tr>
<td>MRI</td>
<td>Imaging of choice for assessment of cognitive impairment</td>
</tr>
<tr>
<td>T1 and T2 MRI</td>
<td>Highly sensitive to old and new infarcts, estimation of white matter disease load, other pathologies (e.g. malignancies, cerebral oedema)</td>
</tr>
<tr>
<td>T2* MRI</td>
<td>Blood and blood products (e.g. haemorrhages), micro-haemorrhages, haemosiderin deposition, amyloid angiopathies</td>
</tr>
<tr>
<td>DWI MRI</td>
<td>Extremely sensitive to early ischaemic changes (recent infarcts including micro-infarcts), integrity of fibre tracts, extensively used for tractography assessing the structural integrity of connecting white matter tracts</td>
</tr>
<tr>
<td>1H-MRS</td>
<td>Measurement of neuronal damage, inflammation, gliosis, differentiation between pathology and normal aging</td>
</tr>
</tbody>
</table>

1H-MRS, proton magnetic resonance spectroscopy; CT, computed tomography; DWI, diffusion-weighted imaging; MRI, magnetic resonance imaging.

### TABLE 6 Meta-analyses relating atrial fibrillation to dementia and cognitive impairment

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Outcome</th>
<th>Inclusions/exclusions</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kwok et al24</td>
<td>Meta-analysis cross-sectional and prospective studies</td>
<td>Dementia</td>
<td>Patients with H/o stroke, 7 studies; n = 2425</td>
<td>OR 2.43; 95% CI: 1.70-3.46; P &lt; .001; I² = 10%</td>
</tr>
<tr>
<td>Kalantarian et al25</td>
<td>Meta-analysis cross-sectional and prospective studies</td>
<td>Cognitive impairment and dementia</td>
<td>Patients with H/o stroke, 7 studies; n = 2409</td>
<td>RR 2.70; 95% CI: 1.82-4.00; I² = 32.3%; P = .18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Excluding patients with or adjusting for H/o stroke 10 studies</td>
<td>RR 1.34; 95% CI: 1.13-1.5</td>
</tr>
</tbody>
</table>

H/o, history of; OR, odds ratio; RR, relative risk.
telemetry monitoring was associated with lower cognitive function. Another small cross-sectional study reported that cognitive performance did not significantly differ by AF burden, but the number of subclinical cerebral ischaemia areas was higher in individuals with persistent compared with paroxysmal AF. More conclusive understanding of the relation of AF burden to cognitive decline and dementia will require larger and longitudinal studies. The relation between AF type and cognitive impairment and dementia is further complicated by the sometimes arbitrary definition of the AF type in the individual patient.

Unfortunately there are no randomized data examining the efficacy of therapies and in particular of individualized management to prevent dementia in individuals with AF. Of interest, the Framingham Heart Study has examined temporal trends in the incidence of dementia and documented that the risk of dementia associated with AF declined over three decades (1970s to the early 2010s). One speculation is that improved anticoagulation and treatment of risk factors were responsible for the declining incidence of dementia in individuals with AF. Another piece of inferential evidence, supporting the benefit of preventing stroke as a strategy to prevent dementia in individuals with AF, are observational meta-analyses (Table 6). In individuals with AF but without stroke at baseline the risk of dementia and cognitive decline is more modest [relative risk 4.00].

It is well established that AF increases the risk of clinical stroke by four- to five-fold, and patients with a clinical history of stroke are at increased risk of developing dementia. It is also well established that AF and dementia, persistent use of warfarin therapy was uncommon (16%), but was associated with the prevention of stroke [hazard ratio (HR) HR 0.74, 95% CI: 0.54-0.99; \( P = 0.047 \)] and death (HR 0.72, 95% CI: 0.67-0.87; \( P < 0.001 \)). A recent updated meta-analysis reported a significant reduction of stroke, stroke or systemic emboli, haemorrhagic stroke, and intracranial bleeding in AF patients with previous stroke or transient ischaemic attack (TIA) receiving NOACs compared with warfarin.

### 5.2 Atrial fibrillation, silent stroke, and cognitive function

It is well established that AF increases the risk of clinical stroke by four- to five-fold, and patients with a clinical history of stroke are at increased risk of developing dementia. However, AF is also associated with cognitive dysfunction ranging from mild impairment to overt dementia, independently of clinical stroke as well as multiple shared risk factors. It is also well established that AF and

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Outcome</th>
<th>Inclusions/exclusions</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hart et al[59]</td>
<td>Meta-analysis</td>
<td>Stroke</td>
<td>6 RCTs warfarin vs placebo; ( n = 2900 )</td>
<td>RR 64% reduction, 95% CI: 49-74%; Absolute reduction: 1° prevention 2.7% per year, 2° prevention 8.48% per year</td>
</tr>
<tr>
<td></td>
<td>adjusted-dose</td>
<td></td>
<td>7 RCTs aspirin vs. placebo or no Rx; ( n = 3900 )</td>
<td>RR 19% reduction, 95% CI – 1 to 35%; 1° prevention 0.8% per year, 2° prevention 2.5% per year</td>
</tr>
<tr>
<td></td>
<td>warfarin and aspirin</td>
<td></td>
<td>8 RCTs warfarin vs aspirin Rx; ( n = 3647 )</td>
<td>RR 38% reduction, 95% CI: 18-52%; 1° prevention 0.7% per year, 2° prevention 7.0% per year</td>
</tr>
<tr>
<td>Ruff et al[60]</td>
<td>Meta-analysis</td>
<td>Stroke and systemic emboli</td>
<td>( n = 29 ) 312 NOAC; ( n = 29 ) 272 warfarin</td>
<td>RR 0.81, 95% CI: 0.73-0.91; ( P &lt; .0001 ); ( I^2 = 47% ); ( P = .13 )</td>
</tr>
<tr>
<td></td>
<td>phase 3 RCTs:</td>
<td></td>
<td>( n = 41 ) 257, no prior stroke; ( n = 17 ) 269, prior stroke</td>
<td>RR 0.85, 95% CI: 0.72-1.01 ( RR = 0.89 ); 95% CI: 0.77-1.02; ( P \text{interaction} = .30 )</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ischaemic stroke</td>
<td>( n = 29 ) 292 NOAC; ( n = 29 ) 221 warfarin</td>
<td>RR 0.92, 95% CI: 0.83-1.02; ( P = .10 ); ( I^2 = 32% ); ( P = .22 )</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Haemorrhagic stroke</td>
<td>( n = 29 ) 292 NOAC; ( n = 29 ) 221 warfarin</td>
<td>RR 0.49, 95% CI: 0.38-0.64; ( P &lt; .0001 ); ( I^2 = 34% ); ( P = .21 )</td>
</tr>
</tbody>
</table>

H/o, history of; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized clinical trial; RR, relative risk.
cognitive impairment share common risk factors, including advanced age, diabetes, hypertension, sleep apnoea, and chronic heart failure. Moreover, data have demonstrated a significant (34%) increase in the risk of cognitive impairment in patients with AF in the absence of clinical stroke, even after adjustment for shared risk factors. Thus, additional mechanisms beyond clinically recognized stroke and shared risk factors may link AF and cognitive impairment. One of the leading potential mechanisms is the occurrence of silent cerebral infarcts, which occur significantly more frequently than clinical stroke and are particularly common in patients with AF.

Detection of cerebral ischaemic events on MRI is based on acute hyperintense lesions on DWI. Brain MRIs reveal evidence of silent cerebral infarcts in a significant percentage of patients with AF. The incidence is related to specifications of MRI and depends on the definition applied. Atrial fibrillation is associated with a more than two-fold increase in the risk of developing silent cerebral infarcts. Although silent infarcts are not associated with clinically apparent acute neurologic deficits, data suggest a significant association between silent infarcts and the development of cognitive decline and dementia. Silent infarcts in patients with AF are believed to be micro-embolic in origin and are identified as small, well-demarcated lesions, often in clusters, and are most prevalent in the frontal lobes. The pattern of silent infarct distribution is similar to that seen in vascular dementia, in which most silent strokes affect frontal circuit components (frontal cortex, basal ganglia, and thalamus) that play an important role in executive functioning. Thus, the term "silent infarct" is probably a misnomer. Because of their small size and location away from speech and motor centres, these micro-injuries do not cause clinically apparent acute focal neurological deficits. However, with the accumulation of silent infarcts and associated repetitive brain injuries over time, micro-injuries may contribute to the development of cognitive impairment. At least one study has specifically addressed the role of subclinical cerebrovascular disease as a mediator between AF and cognitive impairment. In a subset of stroke-free participants in the ARIC study who underwent repeat brain MRI after approximately 12 years, AF was associated with cognitive decline only in those patients who had developed incident silent cerebral infarcts.

There is a paucity of evidence regarding the effect of anticoagulation on silent cerebral infarcts and the risk of cognitive impairment. One recent study addressed this issue by evaluating the time in therapeutic range (TTR) as an indicator of the effectiveness of warfarin anticoagulation in patients with AF. These investigators observed a consistent increase in the risk of dementia as the percentage of TTR decreased. The association between warfarin therapy and dementia was "U"-shaped, with increased risk of dementia among patients with overexposure and underexposure to warfarin [i.e. supra-therapeutic and sub-therapeutic international normalized ratios (INR)s]. This may be due to cumulative brain injury from cerebral microbleeds and silent infarcts, respectively. Recent observational data also suggest that delaying warfarin therapy in patients with AF and no history of dementia, including patients at low as well as high risk for stroke, significantly increases the risk for developing incident dementia.

5.3 | Atrial fibrillation and cognitive function in the absence of stroke

Longitudinal studies have shown that dementia is more common in patients diagnosed with AF even in the absence of stroke. A meta-analysis of eight prospective studies evaluating the relationship between AF and incident dementia in patients without stroke and baseline normal cognitive function included a total of 77,668 patients of whom 15% had AF. After a mean follow-up of about 8 years, 6.5% of patients developed dementia. Atrial fibrillation was independently associated with increased risk of incident dementia (HR 1.42, 95% CI: 1.17-1.72; P < .001). This result was confirmed by a longitudinal analysis from the Cardiovascular Health Study including 5150 participants without baseline history of stroke. Incident AF occurred in 11% of patients, with faster decline in mean cognitive function scores, measured using the Modified Mini Mental State Examination (3MSE), compared with patients in sinus rhythm. Although both AF and dementia are diseases of aging, in two large observational studies the highest RR of dementia was observed in younger AF patients <70 years of age. A recent cross-sectional study indicated that in individuals with heart failure with reduced and preserved systolic ejection fraction, AF was associated with an adjusted higher odds of presence and severity of prevalent cognitive impairment (≥80 years) the relationship between AF and dementia seems to be mostly mediated by concomitant risk factors.

The relationship between AF and cognitive decline may occur through a variety of pathological mechanisms. Given the relationship between AF and stroke, vascular dementia may be an obvious contributor to cognitive decline, encompassing both multi-infarct dementia and SVD dementia. The second form of dementia in AF patients is Alzheimer’s disease, which is the most common type of dementia overall. Atrial fibrillation has been identified as a risk factor for Alzheimer’s disease. Alzheimer’s disease is the result of accumulation of abnormally folded beta-amyloid and tau proteins forming cerebral plaques which exert cytotoxic effects leading to cerebral atrophy. Interestingly, misfolded atrial natriuretic peptides may lead to development of amyloid fibrils and deposits in the atria of elderly patients with AF causing a specific atrial cardiomyopathy classified as EHRA IS IVa. However, if AF and Alzheimer’s disease share a common link with regards to protein misfolding and
amyloidogenesis, it does not appear to be through the APOE ε4 allele.\(^92\) Other studies suggest that the occurrence of Alzheimer’s disease is related to hypoperfusion, inflammation, oxidative stress, and endothelial dysfunction.\(^93-95\) All these factors may be induced by several non-cardiac diseases resulting in an atrial cardiomyopathy which in turn, leads to AF\(^94\) in the sense of both AF and Alzheimer’s disease being the result of third confounding factors. Additionally, several circulating biomarkers of oxidative stress, inflammation, and endothelial dysfunction are elevated during AF.\(^91,96,97\) These factors are also linked to cerebral SVD; therefore, AF may provide a specific milieu for non-stroke related cognitive decline and dementia. For example, hippocampal atrophy in AF patients may be mediated by altered cerebral perfusion due to irregular R-R intervals, abnormal or rapid heart rate, and reduced blood pressure caused by AF, since the hippocampus is one of the most perfusion-sensitive structures of the brain.\(^94,98\)

Interestingly, patients with AF had lower total brain volume when compared with those without AF, independent of cerebral emboli in a large cross-sectional study.\(^102\) In addition, recently, AF was associated with a decrease in total cerebral blood flow and brain perfusion in an unselected elderly cohort.\(^103\) These results may, at least in part, explain the association of AF with reduced relative brain volume and cognitive impairment.

A schematic overview of the various mechanisms, through which AF may lead to cognitive impairment is illustrated in Figure 1.

A number of trials are currently examining, as the primary or secondary outcome, the effect of different therapies including anticoagulation and of different interventions on cognitive function in patients with AF. A non-exhaustive list of such studies is found in Table 8.

The results of these studies will help to improve our understanding of the relationship between AF and cognitive function and provide us with more data for possible prevention of cognitive decline by treatment of AF.

It should also be noted that, conversely, impairment of cognitive function per se might have a negative impact on therapy adherence and medication intake\(^104,105\) and might thus adversely affect treatment effectiveness and outcome in patients with arrhythmias.

### 5.4 Assessment of cognitive function in atrial fibrillation patients in clinical practice

Despite increasing awareness about the relationship between AF and cognitive decline, clinical guidelines for the management of AF do not specifically include assessment of cognitive function in the diagnostic work-up. With increasing prevalence of cognitive impairment in the elderly\(^106\) and given that the highest RR of cognitive decline is in AF patients >70 years of age, healthcare professionals who treat AF patients should be able to diagnose, and assess risk factors for cognitive impairment appropriately.

Assessment of cognitive function should be multifaceted (see Table 3), and psychometric testing is just one component. Numerous validated tools are available to assess cognitive function, varying from brief screening tools, which take 1-8 minutes to complete among elderly patients, to more complex time-consuming neuropsychological batteries (see Table 4). Brief screening tools may be most applicable when cognitive impairment is suspected among AF patients, whereas more comprehensive assessments may be performed after appropriate referral to a geriatrician or neurologist. Other factors determining the choice of test include the time available with the patient, the setting (office-based or inpatient), the patient’s ability to speak English (some tools are not translated and/or validated in other languages), and the purpose of the assessment.
(screening vs. confirmatory). In practical terms, any of the brief tests could be used, although the most common is the GPCOG. In research settings, the Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MOCA) have been commonly used. Informant questionnaires, such as the second step of the Montreal Cognitive Assessment (MOCA), have been commonly used in research settings, the Mini Mental State Examination (MMSE) and the GPCOG or the IQCODE, provide important additive information, since they assess a patient's change over time from someone who knows the person well. This level of detail may not always be feasible, however, and may be more suited for comprehensive geriatric or neurological assessment.

5.5 Prevention of cognitive dysfunction in atrial fibrillation patients

Since the precise mechanism(s) of cognitive disorders in patients with AF is not fully known, the optimal way to prevent cognitive dysfunction for a given patient remains to be established. Considering the mechanisms of cognitive impairment described in the sections above, several therapies may be considered (see “Recommendations”). Both disease states share common risk factors that include aging, smoking, hypertension, diabetes, sleep apnoea, physical inactivity, vascular disease, inflammation, and heart failure. Many of these risk factors represent modifiable targets for preventative therapies and if treated early may lower the risk of both diseases.

Stroke prevention is the principal priority in the management of AF and integrated approaches such as the Atrial Fibrillation Better Care (ABC) pathway (Avoid stroke, Better symptom management, Cardiovascular and comorbidity risk reduction) may improve AF management. Stroke prevention therapy, particularly oral anticoagulation, applied to the appropriate patients according to risk stratification proposed in scientific guidelines may reduce the risk of dementia. Fridberg and Rosenqvist studied 444 AF patients over 1.5 million years at risk. Anticoagulation use was in 60% of the patients with the primary anticoagulant used warfarin (94%). In AF patients not treated with anticoagulation, 60%
were on aspirin. In multivariate analysis, the strongest predictors of dementia were in order: age (HR per decade 2.19, 95% CI: 2.16-2.22), Parkinson’s disease (HR 2.46, 95% CI: 2.25-2.69), absence of oral anticoagulation treatment (HR 2.08, 95% CI: 1.73-2.53), and alcohol abuse (HR 1.53, 95% CI: 1.41-1.66).

In patients managed long term with vitamin K antagonists (VKAs), for example, TTR is inversely associated with new-onset dementia.114 Risk of dementia is augmented in AF patients who are frequently over anticoagulated or receiving antiplatelet therapy.112 However, dementia can have a confounding effect on maintenance of TTR, and oral anticoagulation in AF patients has not been consistently associated with either improved cognitive function or less hippocampal atrophy.98,109,113 Anticoagulation with warfarin neither influenced the reduction of total brain volume nor cognitive function in individuals with AF.102 Non-vitamin K antagonist oral anticoagulant therapy may reduce the incidence of brain microhaemorrhage compared with VKAs,60 but whether NOACs improve long-term cognitive function is currently unknown. A recent community-based study provided some optimism in this regard and found that NOAC therapies were associated with lower stroke and dementia rates compared with warfarin.114 Considering the incidence of dementia in AF, only trials with large numbers of patients and extended long-term follow-up would be able to firmly establish the possible benefit of oral anticoagulation on the subsequent risk of cognitive decline.

Preventing early onset of AF through lifestyle or risk factor modification could delay the onset and progression of cognitive decline. Prevention and early management of smoking, excess alcohol consumption, hypertension, obesity, diabetes, and sleep apnoea may reduce the onset and/or progression of AF115 with concomitant reductions in stroke and possibly cognitive function. However, such risk factor modifications may have independent positive effects on cognitive function regardless of the development of AF. It is also unclear if aggressive modification should start at the time of onset of AF. Lifestyle modification may also reduce the risk of cognitive decline in AF patients. Prevention of cognitive dysfunction may include general measures proposed in the treatment and management of vascular dementia or Alzheimer’s disease. Several trials have tested the effects of physical activity and cognitive training in Alzheimer’s disease and have shown some evidence of efficacy on cognitive endpoints.116 Most of the trials, however, had short follow-up periods. Further evidence is needed to confirm the optimal design and dose of interventions, the appropriate target population, and the efficacy of such interventions. Innovations such as the development of multi-domain interventions and the use of biomarkers or genetic profiles to better target higher-risk patients are being assessed in ongoing trials. However, differentiating the AF-dependent or AF-independent effects of lifestyle and risk factor modifications remains a major challenge.

There are no robust data to affirm that therapy for rhythm control with medication or “successful” AF catheter ablation can prevent cognition disorders in AF patients. Atrial fibrillation catheter ablation may not eliminate AF in the majority of patients, but rather attenuate overall AF burden. Follow-up data beyond 5 or 10 years are limited, and suggest that 2-3% of “successfully” ablated patients will have recurrences annually.117-120 Furthermore, many of these recurrences may be asymptomatic and the prognostic implication of asymptomatic episodes on both stroke risk and cognitive function is unknown.121-123 Catheter ablation as a specific therapeutic approach to lower risk of stroke and dementia is discussed in the Catheter Ablation section.

In patients with persistent AF for whom which rhythm control is not pursued, atrioventricular (AV) node ablation with pacemaker implantation that restores a predictable R-R interval and heart rate has been shown, in a small study, to improve frontal and temporal blood flow and improve memory and learning.124

Recommendations on the prevention of cognitive dysfunction in AF patients are made in the Recommendations section. Most of these recommendations are consistent with those of international guidelines107 and are not necessarily unique to those patients with AF and cognitive dysfunction.

6 | OTHER ARRHYTHMIAS AND COGNITIVE DYSFUNCTION

6.1 | Cognitive dysfunction in patients with regular supraventricular tachycardias

Recurrent supraventricular tachycardias in children and adolescents, mediated by AV nodal re-entry or by accessory pathways, were shown to be associated with cognitive deficits in 48% of such patients, when assessed prior to catheter ablation.125 Whether an early catheter ablation of supraventricular arrhythmia would affect the cognitive status of such patients needs further investigation.

6.2 | Cognitive impairment after cardiac arrest

6.2.1 | Brain injury after non-fatal cardiac arrest

Cardiac arrest occurs in two different settings, in-hospital and out-of-hospital, with completely different prognosis, for obvious reasons. As cardiac arrests that occur in a hospital context are usually immediately attended, the primary focus of the study of brain injury after cardiac arrest has been among survivors of out-of-hospital cardiac arrest (OHCA).126 In this setting, brain damage is caused by cerebral hypoperfusion and its severity depends on the time of such deficit127; the proportion of cardiac arrest survivors who present with some degree of brain damage ranges from 35% to 100%.128,129 The working group of Chun-Lim and colleagues has delineated three scenarios that are clearly related to the duration of brain hypoperfusion: (i) patients with early recovery of brain function without any sequelae, usually associated with opportune resuscitation and/or early recovery of consciousness (<3 days after OHCA); (ii) patients with extensive damage, associated with prolonged coma (>7 days after OHCA); and (iii) an intermediate group between those extremes.130 They report that a coma duration of <3 days results in a better
DAGRES ET AL.

1996, Grubb et al139 demonstrated in a population of 35 patients especially episodic memory dysfunction. This finding is not new, in patients who suffered cardiac arrest showed cognitive impairment, reported that even after therapeutic hypothermia, 52% of the impairment after the event, but the total population showed at least of coma, with responsiveness after 24 hours but with remaining con-

In summary, minimising and treating the complications originating from a cardiac arrest are almost as important as treating the arrest itself. Physicians should perform appropriate follow-up and referral to a specialized centre that can offer appropriate post-cardiac arrest care in order to minimise the extent of brain damage and to avoid adverse outcomes, since the ultimate success of medical therapy is not only survival, but preservation of quality of life.

6.3 | Cardiac implantable electronic devices and cognitive dysfunction

Patients requiring cardiac implantable electronic devices (CIEDs) are generally older and as such may have associated cognitive dysfunction. It has also been shown that patients with severe bradycardia or high-grade AV block may show impaired cognitive function.149–151

Bradycardia is also more common in patients treated for dementia with cholinesterase inhibitor drugs (adjusted HR 1.4, 95% CI: 1.1-1.6) and increases the risk of syncope, CIED need, and falls.152 A
retrospective study showed that patients with cognitive dysfunction were more likely than those without cognitive deficits to be implanted with a pacemaker, even after adjusting for clinical risk factors. Treatment of both permanent or transient bradycardia with CIEDs has been shown to improve cognition in a number of small trials.

Although it may be inferred that patients with cognitive impairment and standard device indications may be at increased risk for device complications, this was not demonstrated in a study by Jama et al. However, the survival was lower than in matched controls suggesting that these patients may have more comorbidities. A small study suggested that the increase in cerebral blood flow after pacemaker implantation for symptomatic bradycardia resulted in improvement in cognitive function. Another small study showed that the improvement was, however, not significant over a 6-12 months follow-up after pacemaker implantation. Ventricular pacing may result in impaired haemodynamics and has been associated with AF, which itself has been associated with multi-infarct dementia. Ventricular pacing was noted to show a trend towards a detrimental effect on the visual memory score. It is well known that CIED may have psychological side effects; this is particularly true for ICD and especially shock therapy. Apart from this psychological effect, there may be a direct effect on cognitive function. Implantable cardioverter-defibrillator implantation with defibrillation testing has been reported to initially result in cognitive dysfunction in 31-39% of patients, as determined by neuropsychological testing. The majority of evidence that catheter ablation may impact cognition was derived from observational studies of AF management. Outcomes after AF ablation with ablation across all age and CHADS2 strata including patients considered at high risk for stroke and patients with prior stroke. In this study, stroke rates in all groups increased with higher CHADS2 scores, including non-AF patients, consistent with the influence of systemic risk factors on stroke risk beyond that of AF.

Catheter ablation of all arrhythmias has peri-procedural risks that may have long-term significant consequences with regard to cognition and dementia risk. Procedural risk with all cardiac left sided procedures may impact long-term cognition due to the presence of peri-procedural thrombus, atheroemboli, cerebral hypoperfusion, sheath and wire manipulation and management, and anaesthesia. In patients that undergo right sided cardiac procedures the risk is anticipated to be lower although paradoxical thromboembolism can occur in the presence of a septal defect. The risk of stroke during left atrial catheter ablation is estimated at approximately 0.5-1%. However asymptomatic or subclinical ischaemic lesions develop in up to 41% of AF ablation patients with an incidence that varies with anticoagulation approach, ablation tool used, and cranial scan protocol. In addition, when peri-procedural transcranial Doppler analysis is used during AF ablation to monitor for emboli, sheath manipulation, removal and insertion of tools, and using of multiple tools within the left atrium are significantly associated with microembolic events. The risk of these lesions is higher (up to 63%) during ventricular arrhythmia ablation with retro-aortic access and long sheaths in the aorta being unique risk factors.

To put these incidences in context with other cardiovascular procedures, the estimated incidence of new brain lesions has been reported to be 8-18% after AF ablation. 11-17% after coronary
The long-term consequences of asymptomatic or subclinical cerebral ischaemic events are unknown. It stands to reason that cranial injury of any type, if persistent or accumulative can impact function. However, cognition is not often tested serially after ablation and the mechanisms that underlie the genesis of these cranial lesions are not fully understood. In the prospective Mesh Ablator vs. Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation (MACPAF) study, high-resolution diffusion-weighted MRI imaging, performed within 48 h after ablation, showed that new brain lesions (range: 1-17) were present in 43.2% of patients. \(^{122}\) Follow-up MRI at 6 months found that 12.5% of the acute brain lesions after ablation formed a persistent scar. Neuropsychological assessment at 6 months found that there was not a significant consequence of these lesions on attention or executive functions, short-term memory, and learning. \(^{122}\) However, other studies such as the ERACE study reported much lower rates of permanent scar indicating the uncertainty in this area. \(^{177}\)

Based on the limited available data, post-AF ablation cognitive dysfunction seems to be common. In a study of 150 patients who underwent ablation, cognitive dysfunction was evident in 28% with paroxysmal AF, 27% with persistent AF, 13% with supraventricular tachycardia, and 0% in control patients with AF who did not undergo ablation. Although these incidences decreased to 13%, 20%, and 3% at 90 days, measurable cognitive dysfunction persisted; access time in the left atrium was the most significant procedural variable of risk. \(^{123}\) Unfortunately in this study, MRI imaging was not performed to determine and correlate this dysfunction with peri-procedural cranial lesions. Neuropsychological outcomes were sought at 3 months in a small study of 23 patients who underwent ablation with post-procedure diffusion-weighted MRI cranial imaging. New cranial lesions were detected in three (14%) patients and one patient suffered a clinical stroke. \(^{161}\) Residual cognitive defects were noted at 3 months with neuropsychological testing, in particular, in verbal memory (one of five cognitive domains); deterioration was observed in 56.5% of ablation patients compared with 17.4% of controls. \(^{178}\)

### 6.5 Implications for electrophysiological procedures and cognitive function

As described in the preceding sections, emerging evidence suggests that various electrophysiological procedures may be associated with cerebral injury and the potential of cognitive decline therefore, it is timely to consider current evidence and guidelines to minimise these risks.

Over recent years considerable research has focused on how to minimise these procedural risks during left sided catheter ablation and in particular AF ablation. The routine use of transoesophageal echocardiography (TOE) to identify pre-existing thrombus at the time of AF ablation remains controversial particularly in an era where most electrophysiological procedures will be performed on uninterrupted anti-coagulation. However, TOE studies have demonstrated that up to 2% of anticoagulated AF patients may have left atrial appendage thrombus or sludge with risk varying according to CHA\(_2\)DS\(_2\)-VASc score. In the most recent AF ablation HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement guidelines, 51% of the writing group members perform a TOE in all patients presenting for AF ablation regardless of presenting rhythm and anti-coagulation status; 71% perform a TOE in patients presenting in AF even on therapeutic anti-coagulation, and 78% perform a TOE in patients not previously anticoagulated even in sinus rhythm. Computed tomography and intra-cardiac echocardiography have both also been used to screen for thrombus but evidence from large comparative studies is lacking.

Evidence suggests that patients with an anticoagulation window period or those requiring bridging are at increased risk of peri-procedural events. Uninterrupted anti-coagulation ensures the full anticoagulant effect in the early post-procedural phase when embolic events are most likely to occur. \(^{179,180}\) In this context, in recent years it has become routine to perform AF ablation on uninterrupted warfarin with a therapeutic INR. Until recently there were little data to support this practice for NOACs however, emerging data from both meta-analyses and a recent large randomized study support the safety of this approach. \(^{179}\) This practice is likely to gain increasing acceptance particularly as reversal agents become more widely available for all NOACs.

Intraprocedurally, a strategy of more aggressive heparin dosing has evolved over the past decade in the light of data that patients who have an activated clotting time (ACT) of <300 s during the procedure have an increased risk of silent cerebral infarction. The current consensus document recommends an ACT target of 300-400 with repeated checks at 15-20 minutes intervals. In addition, echocardiographic data have demonstrated that thrombus may form on sheaths immediately following trans-septal puncture; as such 77% of Consensus Document Writing Group \(^{181}\) members give heparin prior to the trans-septal puncture.

Less data exist for ablation of ventricular arrhythmias although a recent study demonstrated the presence of new silent cerebral infarction in 7 of 12 patients having ablation of ventricular tachycardia originating from the left ventricle. The majority of these patients underwent ablation via a retrograde trans-aortic approach and the target ACT was 300-400 seconds. Whether the incidence would be lower using a trans-septal approach is unknown.

Similarly, limited data exist regarding the impact of device implantation on cognitive function and these have been discussed in the Cognitive Impairment after Cardiac Arrest section. Until more comprehensive data are available it seems prudent to follow recommendations in the 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal ICD programming and testing even though data that such an approach minimises cognitive impact are
TABLE 9 Knowledge gaps and areas for further research

<table>
<thead>
<tr>
<th>General dementia-related research domains&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Knowledge gap(s)</th>
<th>Further research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distinguishing progression of normal aging from pre-clinical cognitive decline</td>
<td>Physiology of normal aging/pathological neurodegenerative processes</td>
<td>• Large international population-based longitudinal studies of aging and dementia &lt;br&gt; • Contribution of vascular conditions, inflammation, oxidative stress, and the immune system to neurodegenerative processes causing dementia</td>
</tr>
<tr>
<td>Identification of the risk factors and risk reduction</td>
<td>Interactions of shared pathological pathways and risk factors</td>
<td>• Interactions of modifiable and non-modifiable dementia risk factors in population-based studies &lt;br&gt; • Feasibility, administration and effectiveness of interventions addressing dementia risk factors</td>
</tr>
<tr>
<td>Early diagnosis, biomarkers and disease monitoring</td>
<td>Effective strategies for cognitive surveillance; Early detection of cognitive impairment; Monitoring of disease progression</td>
<td>• Interventions for timely and accurate diagnosis of cognitive impairment or dementia at the primary health-care level. Better characterization of different dementia types &lt;br&gt; • Strategies for longitudinal surveillance of healthy individuals to distinguish (and timely diagnose) pre-clinical neurodegenerative diseases with cognitive impairment vs. normal aging &lt;br&gt; • Validation and standardization of available cerebrospinal fluid and brain imaging biomarkers of dementia for research and clinical use &lt;br&gt; • Development and validation of novel biological, genetic, behavioural or cognitive biomarkers with predictive value at pre-dementia stages</td>
</tr>
<tr>
<td>Prevention of cognitive impairment/dementia</td>
<td>Effective preventive strategies in general population</td>
<td>• Exploring single- and multi-domain approaches for primary and secondary prevention of dementia based on evidence on risk/protective factors and the relationship with other chronic diseases &lt;br&gt; • Prevention studies need to start in mid-life and have a long follow-up to identify “windows of opportunity” for effective interventions</td>
</tr>
<tr>
<td>Pharmacological and non-pharmacological clinical—translational research on dementia diagnosis and treatment</td>
<td>Effective dementia-specific therapies are not available yet</td>
<td>• Identification, validation and implementation of better defined outcome measures for clinical trials of cognition, function and other biomarkers of neurodegenerative diseases causing dementia &lt;br&gt; • Improvement in differentiation of dementia types &lt;br&gt; • Improvement in the selection of patients eligible for clinical trials of cognitive impairment or dementia &lt;br&gt; • Investigation of combination therapies for dementia and diversification of investigational therapeutic approaches (pharmacological and non-pharmacological interventions)</td>
</tr>
</tbody>
</table>

AF-specific research domains

| Association of AF with cognitive impairment or dementia | Underlying mechanisms beyond clinically overt strokes, silent strokes and aging are poorly understood | • Significance and contribution of cerebral hypoperfusion due to irregular heart rhythm and impaired cardiac function in AF patients, AF-associated hypercoagulability and OAC-related cerebral micro-bleeds to cognitive deterioration and development of dementia <br> • Association of AF burden (i.e. paroxysmal vs non-paroxysmal AF) with cognitive status <br> • Potential role of atrial cardiomyopathy in the development of cognitive impairment/dementia |
| Time-course of cognitive impairment in AF patients | Mechanism(s) of accelerated development of dementia in AF patients | • Large prospective population-based studies on AF and non-AF patients to identify the time-course of cognitive deterioration by AF status and risk factors for accelerated dementia, thus providing a roadmap for prevention strategies <br> • Identification and validation of clinical predictors and biomarkers to identify AF patients at increased risk of cognitive impairment/dementia |
| Rhythm control and other strategies, including ablation, for AF burden reduction | Short- and long-term effects on cognitive function in AF patients | • Better representation of elderly and other AF patients with, or at risk for cognitive impairment or dementia in future rhythm control and AF ablation studies <br> • Prospective investigation of the effects of rhythm control, AF ablation and other strategies for AF burden reduction on cognitive function and prevention, attenuation or delay of cognitive impairment/dementia <br> • Prospective investigation of the effects of different ablation energy sources (e.g. radiofrequency, cryoablation) on cognitive function |

(Continues)
TABLE 9 (Continued)

<table>
<thead>
<tr>
<th>Knowledge gap(s)</th>
<th>Further research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacological rate control therapies in AF; AV node ablation with permanent pacemaker implantation for rate control in AF</td>
<td>Short- and long-term effects on cognitive function in AF patients</td>
</tr>
<tr>
<td></td>
<td>• Prospective investigation of the effects of strict vs. lenient rate control on cognitive function in AF patients including those with cognitive impairment or dementia</td>
</tr>
<tr>
<td></td>
<td>• Better representation of elderly and other AF patients with, or at risk for cognitive impairment or dementia in future prospective studies investigating the effects of AV node ablation with permanent pacemaker implantation on cognitive function and prevention, attenuation or delay of cognitive impairment or dementia</td>
</tr>
<tr>
<td>VKA, NOACs and non-pharmacological (LAAO) thromboprophylaxis in AF</td>
<td>Long-term effects on cognitive function in AF patients</td>
</tr>
<tr>
<td></td>
<td>• Prospective studies of VKA, NOACs and LAAO long-term effects on cognitive function in AF patients with baseline normal cognitive status, cognitive impairment or dementia</td>
</tr>
<tr>
<td></td>
<td>• Assessment of benefits of VKA, NOACs for reduction of cognitive decline among patients with micro-haemorrhages</td>
</tr>
<tr>
<td></td>
<td>• Identification and validation of clinical/biomarker predictors of cognitive impairment/dementia in anticoagulated AF patients or those with LAAO</td>
</tr>
<tr>
<td></td>
<td>• Studies on the consequences of non-adherence or permanent OAC discontinuation in AF patients with cognitive impairment or dementia</td>
</tr>
<tr>
<td>Screening for asymptomatic AF</td>
<td>Asymptomatic AF-associated risk of cognitive impairment</td>
</tr>
<tr>
<td></td>
<td>• Assessment of cognitive impairment and dementia in patients with asymptomatic AF</td>
</tr>
<tr>
<td></td>
<td>• Assessment of the effect of asymptomatic AF treatment on prevention, attenuation or delay of cognitive impairment or dementia</td>
</tr>
<tr>
<td>Early AF detection and treatment</td>
<td>Effects of early aggressive rhythm control on cognitive function</td>
</tr>
<tr>
<td></td>
<td>• Studies with pre-specified primary endpoint of cognitive function</td>
</tr>
<tr>
<td></td>
<td>• Inclusion of elderly and other AF patients with, or at risk for cognitive impairment or dementia</td>
</tr>
<tr>
<td>Primary prevention of AF</td>
<td>Effective interventions for primary prevention (ongoing research)</td>
</tr>
<tr>
<td></td>
<td>• Effects of dietary intervention, improved blood pressure control and other risk factors control on cognitive function in patients at risk of AF and cognitive impairment/dementia, and in non-AF patients with cognitive impairment/dementia</td>
</tr>
</tbody>
</table>

Other arrhythmia-specific research domains

| SCD risk assessment and SCD prevention                                         | Effective strategies in individuals with cognitive limitations                                      |
|                                                                                  | • Improvement of non-invasive risk assessment and identification of screening tools applicable to older and other patients with, or at risk for cognitive impairment or dementia |
|                                                                                  | • SCD prevention studies to include cognitive function endpoints                                |
| Catheter ablation of ventricular arrhythmias                                    | Short and long-term effects in individuals with cognitive limitations                             |
|                                                                                  | • Better understanding of the role of catheter ablation of ventricular arrhythmias in older and other patients with, or at risk for cognitive impairment/dementia, including studies of competing risk of death caused by ventricular arrhythmias vs other causes |
|                                                                                  | • Further studies on the impact of left sided and trans-septal vs. trans-aortic access on cognitive function |
| ICD for primary and secondary prevention                                        | Short- and long-term effects in patients with cognitive limitations                              |
|                                                                                  | • Studies on ICD implantation outcomes including procedural complications, QALY gain, healthcare costs and competing risk of death in patients with cognitive impairment or dementia |
|                                                                                  | • Studies estimating life extension with ICD and end-of-life issues in patients with cognitive impairment or dementia |
|                                                                                  | • Further research on impact of antitachycardia pacing vs. defibrillation on cognitive function |
| CRT                                                                             | Effects in patients with cognitive limitations                                                    |
|                                                                                  | • Studies of the impact of CRT, with or without ICD, on QoL and cognitive function in patients with, or at risk for cognitive impairment or dementia |

AF, atrial fibrillation; AV, atroventricular; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; LAAO, left atrial appendage occlusion; NOACs, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulation; QALY, quality-adjusted life-years; QoL, quality of life; SCD, sudden cardiac death; VKA, vitamin K antagonist.

*Compiled and modified from the Refs.131–133,185–187 (for details on the quality of care, delivery of care and services for individuals with dementia and public awareness and understanding see the cited documents).

lacking. These include the 2A recommendation that: “It is reasonable to omit defibrillation efficacy testing in patients undergoing initial left pectoral transvenous ICD implantation procedures where appropriate sensing, pacing, and impedance values are obtained with fluoroscopically well-positioned right ventricular leads”; and the Class 3 recommendation that “Defibrillation efficacy testing at the time of
implications of a transvenous ICD should not be performed on patients with a documented non-chronic cardiac thrombus, AF or atrial flutter without adequate systemic anticoagulation, critical aortic stenosis, unstable coronary artery disease, recent stroke or TIA, haemodynamic instability, or other known morbidities associated with poor outcomes”.

Regarding the impact of left atrial appendage occlusion (LAAO) procedures on cognitive function, MRI-detected new acute brain lesions were detected in 12 of 23 (52%) patients after LAAO procedures using the Amulet, Occlutech, or LAmbre devices. New brain lesions were associated with a higher number of left atrial appendage angiographies although there was no apparent impact on cognitive testing. Procedural stroke, typically related to air embolism, has also been reported with the Watchman device in the PROTECT trial, although impact on long-term cognition is unknown. However, any long-term impact on cognition has not been reported.

7 CURRENT KNOWLEDGE GAPS, FUTURE DIRECTIONS, AND AREAS FOR RESEARCH

Global management of dementia syndromes has been recently set as a public health priority, and the World Health Organization has prioritized seven research domains to reduce the global burden of dementia: (i) Prevention, identification, and reduction of risk; (ii) Quality of care for people with dementia and their carers; (iii) Delivery of care and services for people with dementia and their carers; (iv) Diagnosis, biomarker development, and disease monitoring; (v) Pharmacological and non-pharmacological clinical—translational research; (vi) Public awareness and understanding; and (vii) Physiology and progression of normal ageing and disease pathogenesis. Other expert groups have also provided recommendations for further progress and improvements in dementia-related research and highlighted knowledge gaps in cardiovascular care of the elderly, including those with cognitive impairment. Declining incidence and age-specific prevalence of dementia in high-income countries implies that dementia risk is modifiable, likely through improved management of cardiovascular risk factors and psychosocial factors. Although dementia-prevention RCTs failed to confirm many signals from observational studies, those RCTs highlighted some key methodological issues to be considered in contemporary trials (Table 9).

Elderly patients with cognitive impairment commonly have mixed pathologies, including cardiovascular disease (e.g. AF and heart failure) but the complexity of shared pathological pathways and risk factors is still poorly understood and warrants further research. Better understanding of the mechanisms and determinants of AF-related cognitive impairment/dementia beyond aging and stroke would inform AF-specific preventive strategies to attenuate and/or postpone cognitive deterioration. Prospective studies addressing the long-term effects of AF treatments directed towards rhythm control, reduction of total AF burden and improvement in cardiac function (i.e. catheter ablation and pharmacotherapy) on cognitive function are needed. Inherent to achieving these targets is consistent utilization of well-validated neurocognitive measures. Also, the effects of lifestyle changes resulting in weight loss, improvement in overall cardio-metabolic risk profile and reduced AF burden need to be investigated. Further research is needed to optimize rate control in AF relative to cognitive function.

Cognitive endpoints were not addressed in the recent large RCTs of OAC (oral anticoagulation: VKA or NOACs) for thromboprophylaxis in AF, with one exception, the Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA) which reported better cognitive function in elderly patients receiving warfarin compared with aspirin. In retrospective observational studies the risk of dementia increased with poor management of VKA (a low TTR), whilst NOAC use was associated with lower risk for dementia compared with warfarin. Observational data on AF patients diagnosed with dementia consistently shows significant VKA underuse or discontinuation even post-stroke, despite similar VKA-related bleeding risk irrespective of the cognitive status. Large prospective studies with pre-specified cognitive outcomes are needed to identify optimal thrombo-prophylactic strategies for AF patients with cognitive function.

### TABLE 10 Interventions to be considered for prevention of cognitive dysfunction in atrial fibrillation patients

<table>
<thead>
<tr>
<th>Pharmacological interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>In relation to AF management</td>
</tr>
<tr>
<td>Oral anticoagulation (early identification of appropriate candidates, improving drug adherence, avoiding warfarin in those with poor TTR, and optimal TTR management)</td>
</tr>
<tr>
<td>Rhythm control</td>
</tr>
<tr>
<td>Antihypertensive treatment</td>
</tr>
<tr>
<td>Treatment of concomitant heart failure</td>
</tr>
<tr>
<td>Non-specific pharmacological interventions:</td>
</tr>
<tr>
<td>Glycaemic control</td>
</tr>
<tr>
<td>Hormone replacement therapy</td>
</tr>
<tr>
<td>Avoid aspirin therapy unless specific clinical indication present</td>
</tr>
<tr>
<td>Alzheimer’s disease-specific pharmacological interventions</td>
</tr>
<tr>
<td>Multifactorial vascular risk factor management</td>
</tr>
<tr>
<td>Targeting blood pressure, cholesterol, diabetes, sleep apnoea, obesity via diet, medication, smoking cessation, and physical activity</td>
</tr>
<tr>
<td>Nutritional interventions</td>
</tr>
<tr>
<td>Low levels of vitamin D and B12, and folate increase risk, but the value of supplementation remains unproven. Calcium supplementation in women has been associated with increased dementia risk. The value of modulating cognitive function based on educational interventions is uncertain.</td>
</tr>
<tr>
<td>Weight loss in obesity</td>
</tr>
<tr>
<td>Others</td>
</tr>
<tr>
<td>Cognitive activities or training</td>
</tr>
<tr>
<td>Physical exercise</td>
</tr>
<tr>
<td>Multi-domain interventions</td>
</tr>
</tbody>
</table>

AF, atrial fibrillation; TTR, time in therapeutic range.
impairment/dementia. Importantly, the effects of early AF treatment or primary AF prevention on cognitive deterioration in patients at risk for both conditions remain to be elucidated.

Elderly patients and those with cognitive impairment/dementia were generally under-represented in catheter ablation and CIED (i.e. ICD and cardiac resynchronization therapy) trials. Studies are needed to better define the risks and benefits of cardiac arrhythmias ablation or CIED implantation, long-term effects of these interventions on cognitive status and optimal strategies for shared decision-making and end-of-life decisions in these patients (Table 9).

8 | RECOMMENDATIONS

Interventions that can be considered for prevention of cognitive dysfunction in AF patients are summarized in Table 10. The writing committee reached consensus on recommendations summarized in Table 11.

REFERENCES

38. Wilber ST, Lofgren SD, Mager TG, Blanda M, Gerson LW. An
30. Young J, Meagher D, Maclullich A. Cognitive assessment of older
28. Laurin D, Masaki KH, White LR, Launer LJ. Ankle-to-brachial index
25. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impair-
34. Li F, Jia XF, Jia J. The informant questionnaire on cognitive decline
23. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors
12. Wilber ST, Lofgren SD, Mager TG, Blanda M, Gerson LW. An
evaluation of two screening tools for cognitive impairment in older


This panel of experts.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.